All In Biotech

NDA 216834 · Ucb INC

Zilbrysq

Zilucoplan Sodium · Subcutaneous

NovelOrphan

CDER novel approval, Oct 17, 2023: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Oct 17, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

18

10 Phase 3, 4 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. FDA's summary: To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive

Therapeutic areas: Neurology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZILBRYSQ · ZILUCOPLAN SODIUM EQ 23MG BASE/0.574ML (EQ 23MG BASE/0.574ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZILBRYSQ · ZILUCOPLAN SODIUM EQ 32.4MG BASE/0.81ML (EQ 32.4 BASE/0.81ML) · SOLUTION, SUBCUTANEOUS · Prescription
  • ZILBRYSQ · ZILUCOPLAN SODIUM EQ 16.6MG BASE/0.416ML (EQ 16.6MG BASE/0.416ML) · SOLUTION, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Zilucoplan" as an intervention, any sponsor and status, largest first.

All 18 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zilbrysq (Zilucoplan Sodium)

2024 spending

$37.1M

Beneficiaries

202

966 claims

Per beneficiary

$183,754

$1,871.89 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$37,118,311

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: UCB

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.